Dosing9 min readUpdated 2026-04-10

    Zepbound Dosing Chart: Week-by-Week Dose Escalation Guide

    See the Zepbound dosing chart, including starting dose, dose-escalation schedule, maintenance dosing, and what to know about missed doses.

    Written by Trimi Medical Team. Medically reviewed by Dr. Asad Niazi, MD, MPH. This article covers the Zepbound dosing chart including starting dose, the FDA-approved escalation schedule, maintenance dosing, and missed-dose guidance.

    Quick links: Tirzepatide treatment, side effects timeline, and 3-month results.

    Standard Zepbound Dosing Chart

    FDA-Approved Zepbound Dose Progression

    Weeks 1-4: 2.5 mg once weekly. Weeks 5-8: 5 mg once weekly. Then, if needed and tolerated, dose may increase in 2.5 mg increments after at least 4 weeks. Potential maintenance doses: 5 mg, 10 mg, 15 mg. Intermediate steps (7.5 mg, 12.5 mg) are commonly used during titration.

    Why the Starting Dose Is Low

    Tirzepatide can cause nausea, vomiting, diarrhea, constipation, and reduced appetite, especially early in treatment. The lower starter dose helps the body adjust before moving to stronger doses. That is why a dosing chart is not just a schedule. It is a tolerability plan.

    The Dose-Escalation Mindset

    Start low at 2.5 mg to allow the body to adjust

    Increase carefully in 2.5 mg steps after at least 4 weeks per dose level

    Slow down if side effects get harder to manage

    Stay longer at a tolerated dose if needed before moving up

    For a detailed look at how side effects track with dose changes, see our tirzepatide side effects week by week guide.

    Maintenance Dosing

    Not every patient lands on the same maintenance dose. Some do well at 5 mg or 10 mg while others eventually move to 15 mg. The right endpoint depends on side-effect tolerance, appetite control, weight-loss response, and clinician guidance.

    For expected results at different stages, see tirzepatide results after 3 months. And to understand how the Mounjaro dosing chart compares, see our companion guide.

    Missed Dose Basics

    If you miss a dose, follow the instructions in the prescribing information and your clinician's guidance. The exact timing matters, and patients should not double up casually without understanding the official instructions. Maintaining a consistent weekly schedule helps optimize treatment outcomes.

    If you are concerned about treatment interruptions, learn about what happens when you stop tirzepatide and how to plan for continuity. For cost-related concerns that might affect consistency, see our Zepbound cost guide.

    Frequently Asked Questions

    What is the starting dose for Zepbound?

    Zepbound is started at 2.5 mg once weekly for the first 4 weeks. This low starting dose helps the body adjust to tirzepatide and reduces the likelihood of severe gastrointestinal side effects during the initial treatment period.

    What does the Zepbound dose escalation schedule look like?

    The FDA-approved weekly escalation framework starts at 2.5 mg for weeks 1 to 4, then moves to 5 mg for weeks 5 to 8. After that, if needed and tolerated, the dose may increase in 2.5 mg increments after at least 4 weeks on the current dose. Potential maintenance doses include 5 mg, 10 mg, and 15 mg, with intermediate steps of 7.5 mg and 12.5 mg commonly used during titration.

    Why does Zepbound start at such a low dose?

    Tirzepatide can cause nausea, vomiting, diarrhea, constipation, and reduced appetite, especially early in treatment. The lower starter dose helps the body adjust before moving to stronger doses. That is why a dosing chart is not just a schedule but a tolerability plan.

    Does everyone on Zepbound need to reach the maximum dose?

    No. Not every patient lands on the same maintenance dose. Some do well at 5 mg or 10 mg while others eventually move to 15 mg. The right endpoint depends on side-effect tolerance, appetite control, weight-loss response, and clinician guidance. The chart should be interpreted as a guide, not a rigid mandate.

    What should I do if I miss a Zepbound dose?

    If you miss a dose, follow the instructions in the prescribing information and your clinician's guidance. The exact timing of when you missed matters, and patients should not double up casually without understanding the official instructions. Contact your healthcare provider if you are unsure.

    How is the Zepbound dosing chart different from Mounjaro?

    Because both Zepbound and Mounjaro use tirzepatide as the active ingredient, the dose-escalation logic is very similar. Both start at 2.5 mg and increase in 2.5 mg steps. The brands may be prescribed under different clinical contexts, but the underlying dose ladder follows the same titration principles.

    Can I slow down my Zepbound dose escalation if side effects are difficult?

    Yes. The dosing chart is a framework, not a race. If side effects get harder to manage at a given dose level, your clinician may recommend staying at that dose longer before increasing, or adjusting the plan based on your individual tolerance. Slowing down escalation is a common and appropriate approach.

    Sources & References

    1. Zepbound prescribing information. FDA.
    2. Zepbound consumer information. Eli Lilly.

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, adjusting, or discontinuing any medication. Individual results vary. Dose adjustments should only be made under medical supervision. Zepbound requires a prescription.

    What does the published clinical evidence show for compounded tirzepatide?

    Peer-reviewed evidence: Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022). Trimi offers compounded tirzepatide starting at $125/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. — SURMOUNT-1, NEJM 2022
    In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. — SURPASS-2, NEJM 2021
    Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. — SURMOUNT-OSA, NEJM 2024

    Key Takeaways

    • Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022)
    • In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. (Source: SURPASS-2, NEJM 2021)
    • Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. (Source: SURMOUNT-OSA, NEJM 2024)
    • Tirzepatide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Zepbound and Mounjaro). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 10, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2107519
    3. Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-023-02597-w
    4. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2023.24945
    5. Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2404881
    6. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) Prescribing Information. FDA.Read Study

    Was this article helpful?

    Keep Reading

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    Can Weight Loss Start After the Second Dose. Read the full clinician-reviewed Trimi guide — practical guidance plus Trimi's $99/mo compounded GLP-1 alternative for context.

    Start your GLP-1 journey — from $99/mo

    Get Started